Table 2.
Summary of the diagnostic efficacy of different liquid biopsy biomarkers in differentiating HCC from healthy controls and liver disease patients.
| Diagnostic techniques | Sensitivity (95%CI) | specificity (95%CI) | Diagnostic odds ratio (95%CI) | Superiority index (95%CI) | Relative sensitivity (95%CI) |
Relative specificity (95%CI) |
|---|---|---|---|---|---|---|
| Diagnostic performance based on HCC vs. healthy control | ||||||
| exosome | 0.877 (0.784-0.933) | 0.824 (0.718-0.896) | 31.504 (12.937-76.719) | 2.797 (0.143-9) | 1 | 1 |
| lncRNA | 0.839 (0.780-0.884) | 0.748 (0.707-0.786) | 14.364 (9.278-22.238) | 1.774 (0.143-7) | 0.978 (0.854-1.133) | 1.013 (0.819-1.249) |
| miRNA | 0.871 (0.844-0.893) | 0.752 (0.706-0.792) | 18.495 (12.843-226.633) | 1.88 (0.2-7) | 1.005 (0.909-1.145) | 0.994 (0.847-1.206) |
| mRNA | 0.942 (0.778-0.987) | 0.583 (0.498-0.664) | 10.983 (5.280-22.847) | 0.538 (0.111-9) | 1.024 (0.851-1.208) | 0.685 (0.445-0.950) |
| circRNA | 0.946 (0.915-0.965) | 0.763 (0.609-0.869) | 55.74 (18.211-170.604) | 3.55 (0.143-3) | 1.057 (0.906-1.218) | 0.931 (0.637-1.228) |
| Diagnostic performance based on HCC vs. liver disease | ||||||
| exosome | 0.785 (0.751-0.816) | 0.722 (0.675-0.764) | 9.511 (7.627-11.860) | 0.593 (0.111-2.333) | 1 | 1 |
| lncRNA | 0.871 (0.806-0.917) | 0.622 (0.541-0.697) | 10.477 (6.793-16.161) | 0.621 (0.111-2.333) | 1.086 (0.948-1.236) | 0.89 (0.674-1.152) |
| miRNA | 0.797 (0.767-0.824) | 0.759 (0.725-0.791) | 11.71 (9.255-14.817) | 0.975 (0.143-2.333) | 1.019 (0.921-1.158) | 1.062 (0.902-1.277) |
| mRNA | 0.949 (0.932-0.962) | 0.935 (0.578-0.993) | 139.514 (26.334-739.120) | 10.621 (7-11) | 1.215 (1.095-1.381) | 1.225 (1.018-1.490) |
| circRNA | 0.812 (0.684-0.896) | 0.737 (0.686-0.783) | 11.386 (5.002-25.920) | 0.945 (0.091-5) | 1.005 (0.760-1.217) | 0.991 (0.628-1.329) |
| cfDNA | 0.792 (0.719-0.850) | 0.739 (0.522-0.880) | 10.381 (4.535-23.765) | 1.028 (0.091-5.05) | 1.001 (0.771-0.208) | 1.02 (0.709-1.350) |